| LP420390-9 | Inpatient beds | DIVISORS | |
| LP420391-7 | Inpatient beds occupied | COMPONENT | 1 |
| LP420392-5 | Inpatient beds occupied by patients with disease of interest | COMPONENT | 1 |
| LP420393-3 | Intensive care unit beds occupied | COMPONENT | 1 |
| LP420394-1 | ICU beds | DIVISORS | |
| LP420396-6 | Inpatient beds occupied | DIVISORS | |
| LP420400-6 | Cabotegravir | COMPONENT | 2 |
| LP420401-4 | Increase or decrease in cases compared to previous reporting period | COMPONENT | 1 |
| LP420402-2 | Percent increase or decrease in cases compared to previous reporting period | COMPONENT | 1 |
| LP420403-0 | Percent increase or decrease in deaths compared to previous reporting period | COMPONENT | 1 |
| LP420404-8 | Percent increase or decrease in cases among healthcare personnel compared to previous reporting period | COMPONENT | 1 |
| LP420405-5 | Percent increase or decrease in deaths among healthcare personnel compared to previous reporting period | COMPONENT | 1 |
| LP420406-3 | Increase or decrease in deaths among healthcare personnel compared to previous reporting period | COMPONENT | 1 |
| LP420407-1 | Cases among healthcare personnel | COMPONENT | 2 |
| LP420408-9 | Hospitalizations | COMPONENT | 2 |
| LP420412-1 | Deaths among healthcare personnel | COMPONENT | 2 |
| LP420419-6 | Number (count) diff | PROPERTY | 4 |
| LP420423-8 | SARS-CoV-2 (COVID-19) and SARS-related CoV RNA | COMPONENT | |
| LP420424-6 | SARS-CoV-2 (COVID-19) and SARS-related CoV | COMPONENT | |
| LP420426-1 | Citrullinated alpha enolase peptide 1 Ab | COMPONENT | 1 |
| LP420443-6 | Influenza virus A and B and SARS-CoV+SARS-CoV-2 (COVID-19) Ag panel | COMPONENT | 1 |
| LP420447-7 | HLA typing comment | COMPONENT | 2 |
| LP420448-5 | HLA-A and B and C (class I) typing panel | COMPONENT | 4 |
| LP420449-3 | Cell growth | COMPONENT | 4 |
| LP420450-1 | Alcian blue stain.with hyaluronidase | METHOD | 1 |
| LP420454-3 | Inner ear 68kD Ab.IgG | COMPONENT | 1 |
| LP420455-0 | Citrullinated alpha enolase peptide 1 | COMPONENT | |
| LP420456-8 | Inner ear | COMPONENT | |
| LP420457-6 | Inner ear Ab | COMPONENT | 1 |
| LP420467-5 | Cytosolic 5'-nucleotidase 1A Ab | COMPONENT | 1 |
| LP420480-8 | Hospital or facility beds utilization panel | COMPONENT | 1 |
| LP420491-5 | IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Functional abilities and goals - discharge | COMPONENT | 1 |
| LP420492-3 | IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Functional abilities and goals - admission | COMPONENT | 1 |
| LP420493-1 | IRF-PAI - Payment source | COMPONENT | 1 |
| LP420494-9 | IRF-PAIv3.0, MDS v1.17.1, 1.17.2 - Self-care - discharge performance | COMPONENT | 1 |
| LP420495-6 | IRF-PAI v3.0, LCDS v4.00 - Current number of unhealed pressure injuries at each stage - admission | COMPONENT | 1 |
| LP420496-4 | IRF-PAI v3.0, LCDS v4.00 - Current number of unhealed pressure injuries at each stage - discharge | COMPONENT | 1 |
| LP420497-2 | IRF-PAI v3.0, LCDS v3.00 - Program interruption dates | COMPONENT | 1 |
| LP420498-0 | IRF-PAI v3.0 - Hearing, speech, and vision - admission | COMPONENT | 1 |
| LP420499-8 | IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Self-care - admission performance | COMPONENT | 1 |
| LP420500-3 | IRF-PAI v3.0, LCDS v4.00 - Bladder and bowel - admission | COMPONENT | 1 |
| LP420501-1 | IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Mobility - discharge performance | COMPONENT | 1 |
| LP420502-9 | IRF-PAI v3.0, MDS v1.17.1, 1.17.2, OASIS E - Prior functioning: everyday activities | COMPONENT | 1 |
| LP420503-7 | IRF-PAI v3.0 - Staff assessment for mental status | COMPONENT | 1 |
| LP420504-5 | Usual ability to swallow | COMPONENT | 1 |
| LP420505-2 | Hematologic cancer | COMPONENT | 1 |
| LP420506-0 | ICU beds | COMPONENT | 1 |
| LP420510-2 | Skindex-16 | METHOD | 21 |
| LP420516-9 | SARS-CoV-2 (COVID-19) specific TCRB gene rearrangements | COMPONENT | 1 |
| LP420517-7 | SARS-CoV-2 stimulated gamma interferon | COMPONENT | 2 |